2011 International Conference on TomoTherapy (ICT) Highlights Widespread Acceptance of the Benefits of Daily Image-Guided IMRT
SUNNYVALE, Calif., Sept. 23, 2011 /PRNewswire via COMTEX/ --
Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, today announced details of the 2011 International Conference on TomoTherapy (ICT), which took place September 16-17, 2011 hosted by the University of Heidelberg, Germany's oldest University and world famous research center for cancer and microbiology. University of Heidelberg was the first institution in Germany to adopt the TomoTherapy® System for daily image-guided, intensity-modulated radiation therapy (DIG-IMRT) with its installation in 2006. The university started treating patients on their second TomoTherapy System in January 2011.
The ICT provides a forum to discuss the clinical capabilities, innovative concepts and ongoing clinical trials for TomoTherapy technology. In attendance this year were approximately 200 participants from around the world, composed of users and non-users of the TomoTherapy System.
Keynote addresses were given by Prof. Steve Webb, Professor of Radiological Physics from Institute of Cancer Research and Royal Marsden NHS Trust, Sutton, UK, and conference chair Prof. Jurgen Debus, Head of the Department of Radiation Oncology, University of Heidelberg. Prof. Webb's talk, titled 'Rotation Radiotherapy: A Revolution in Radiotherapy' reviewed the evolution of IMRT and highlighted the superiority of the dose modulation techniques available today. Prof. Debus' presentation 'Photons meet Particles' addressed the potential new standards particles can set in the future, underlining the limitations and open questions of this technique today. He insisted on the fact that it is not about "either photons or particles", but about finding the right balance and indications.
"We were extremely pleased with the strong international representation and high quality of clinical and technical presentations at this year's conference," said Prof. Debus. "The ICT provides the medical community with an important forum for translating the benefits of new technologies into real improvements in the treatment of cancer."
Presentations highlighted TomoTherapy System usage for central nervous system, head & neck, breast, gastrointestinal, prostate and lung cancer treatments. Attendees also presented on the advantages of the TomoTherapy System in hemato-oncological, pediatric applications and adaptive radiation therapy, dosimetry, treatment planning, QA and new technical developments.
Abstracts from the ICT will be published in the October issue of Strahlentherapie und Onkologie, the oldest oncological journal in the world, which is the official journal of the scientific societies in Germany, Austria, Hungary and Romania.
"The level of interest in this year's ICT is a testament to the TomoTherapy System's evolution from a unique technical approach to a wide-spread IMRT solution that's in practice worldwide," said Euan Thomson, Ph.D., president and CEO of Accuray. "We are grateful to the clinicians from University of Heidelberg for hosting this important scientific exchange and for giving me the opportunity to speak to attendees about Accuray's personalized approach to advancing cancer care."
More information on the ICT can be found on the conference website: www.tomoconference2011.com.
About Accuray
Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is the premier radiation oncology company that develops, manufactures and sells personalized, innovative treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The Company's leading-edge technologies - the CyberKnife and TomoTherapy Systems - are designed to deliver radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image guided radiation therapy, and adaptive radiation therapy. To date, more than 200,000 patients worldwide have been treated using the company's technologies and more than 575 systems have been installed in leading hospitals around the world. For more information, please visit www.accuray.com.
Safe Harbor Statement
The foregoing may contain certain forward-looking statements that involve risks and uncertainties, including uncertainties associated with the medical device industry. Except for the historical information contained herein, the matters set forth in this press release, including statements regarding clinical capabilities, clinical trials, clinical applications, and clinical outcomes are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date the statements are made and are based on information available at the time those statements are made and/or management's good faith belief as of that time with respect to future events. You should not put undue reliance on any forward-looking statements. Important factors that could cause actual performance and results to differ materially from the forward-looking statements we make include: clinical capabilities, clinical trials, clinical applications, clinical outcomes and other risks detailed from time to time under the heading "Risk Factors" in our report on Form 10-K for our 2011 fiscal year filed on September 19, 2011 and our other filings with the Securities and Exchange Commission. The Company's actual results of operations may differ significantly from those contemplated by such forward-looking statements as a result of these and other factors. We assume no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws.
SOURCE Accuray Incorporated